Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Datadog Inc (DDOG) Price & Performance

BioNano Genomics IncTrade
Datadog IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Datadog Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Datadog Inc trades at $265.42 (market cap $96.37B). The key difference: Datadog Inc is far larger — about 7300.8× BioNano Genomics Inc's market cap, and Datadog Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGODDOG
Market Cap
$13.20M$96.37B
Sector
HealthTechnology
52-Week High
$4.92$277.49
52-Week Low
$1.09$102.62
Enterprise Value
$15.81M$92.90B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Datadog Inc

Datadog (DDOG) trades at $260.24, up 1.05% on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.58. Revenue growth remains robust, climbing from $1.7B in 2022 to $3.4B in 2025, though net income margin is modest at 3.69%. The company's acquisition of Adaptive ML aims to bolster its AI capabilities, positioning it for sustained growth in cloud observability.

The outlook for DDOG is positive, driven by solid revenue expansion and strategic AI investments, but high valuation multiples (P/E of 667.28, P/S of 25.79) pose risks if growth slows. Investor sentiment is overwhelmingly bullish, with 83% of analysts rating it a buy, though competition and market volatility require monitoring. The stock's momentum and institutional backing suggest further upside, contingent on continued execution and market conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG